Phase I/II of XB2001 (Anti-IL-1a True Human Antibody) in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Patients with Advanced Pancreatic Cancer (1-BETTER)
Summary
The purpose of this phase I/II trial is to evaluate the safety and tolerability of XB2001 in combination with ONIVYDE and 5-fluorouracil (+folinic acid) in patients with advanced pancreatic cancer.
General Information
NCT#: NCT04825288
Study ID: 2020-PT049
Trial Phase: Phase I/II
Trial Sponsor: XBiotech
Therapies Used in This Trial: Fluorouracil, irinotecan liposome injection, XB2001